GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

GeneDx Holdings faces a securities fraud class action lawsuit for failing to disclose material information about its Fabric Genomics acquisition performance. The company reported a significant drop in adjusted gross margin (74% to 69%), missed revenue estimates, and took a $31.2 million impairment loss on the acquisition. Following these disclosures on May 4, 2026, GeneDx shares declined 49.2%. Investors who purchased shares between April 16, 2025 and May 4, 2026 can file lead plaintiff applications by August 3, 2026.